NewAmsterdam Pharma Company NV (NASDAQ:NAMS) price on Friday, December 27, fall -1.41% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $25.86.
A look at the stock’s price movement, the close in the last trading session was $26.23, moving within a range at $25.71 and $26.325. The beta value (5-Year monthly) was -0.001. Turning to its 52-week performance, $27.29 and $10.50 were the 52-week high and 52-week low respectively. Overall, NAMS moved 24.09% over the past month.
NewAmsterdam Pharma Company NV’s market cap currently stands at around $2.76 billion, with investors looking forward to this quarter’s earnings report slated for in January.
Wall Street analysts have also projected the company’s year-on-year revenue to grow to 30.59M, representing a 135.22% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NAMS is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend NAMS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NAMS’s current price about 10.97% and 18.47% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 62.41, while 7-day volatility ratio is 3.74% and 6.29% in the 30-day chart. Further, NewAmsterdam Pharma Company NV (NAMS) has a beta value of 0.04, and an average true range (ATR) of 1.44. Analysts have given the company’s stock an average 52-week price target of $37, forecast between a low of $36 and high of $45. Looking at the price targets, the low is -39.21% off current price level while to achieve the yearly target high, price needs to move -74.01%. Nonetheless, investors will most likely welcome a -43.08% jump to $37 which is the analysts’ median price.
If we refocus on NewAmsterdam Pharma Company NV (NASDAQ:NAMS), historical trading data shows that trading volumes averaged 0.99 over the past 10 days and 739.54K over the past 3 months. The company’s latest data on shares outstanding shows there are 92.17 million shares.
The 52.87% of NewAmsterdam Pharma Company NV’s shares are in the hands of company insiders while institutional holders own 35.74% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.59 million on 2024-11-29, giving us a short ratio of 3.73. The data shows that as of 2024-11-29 short interest in NewAmsterdam Pharma Company NV (NAMS) stood at 466.0 of shares outstanding, with shares short rising to 0.72 million registered in 2024-10-31. Current price change has pushed the stock 131.51% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NAMS stock continues to rise going into the next quarter.
